To date, the inhibitors of renin-angiotensin-aldosterone system (RAAS) are the primary medications for renal fibrosis and myocardial remodeling, but the application of these drugs is limited when serum creatinine rises above 3.5 mg/dL [6, 7]. The gene discussed is REN; the disease is renal fibrosis.